{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T23:17:00Z","timestamp":1776899820241,"version":"3.51.2"},"reference-count":40,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["2013-IG-AL00545"],"award-info":[{"award-number":["2013-IG-AL00545"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000014","name":"Canadian Blood Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000014","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.autrev.2016.02.006","type":"journal-article","created":{"date-parts":[[2016,2,13]],"date-time":"2016-02-13T16:15:31Z","timestamp":1455380131000},"page":"510-512","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Targeting Fc\u03b3Rs to treat antibody-dependent autoimmunity"],"prefix":"10.1016","volume":"15","author":[{"given":"Xiaojie","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan H.","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2016.02.006_bb0005","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fcgamma receptors as regulators of immune responses","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2016.02.006_bb0010","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/ni.2939","article-title":"Type I and type II Fc receptors regulate innate and adaptive immunity","volume":"15","author":"Pincetic","year":"2014","journal-title":"Nat Immunol"},{"key":"10.1016\/j.autrev.2016.02.006_bb0015","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.tmrv.2007.12.001","article-title":"The mechanisms of action of intravenous immunoglobulin and polyclonal anti-d immunoglobulin in the amelioration of immune thrombocytopenic purpura: what do we really know?","volume":"22","author":"Crow","year":"2008","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.autrev.2016.02.006_bb0020","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1172\/JCI74572","article-title":"Shifting FcgammaRIIA-ITAM from activation to inhibitory configuration ameliorates arthritis","volume":"124","author":"Ben Mkaddem","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2016.02.006_bb0025","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/art.23284","article-title":"Induction of macrophage secretion of tumor necrosis factor alpha through fcgamma receptor IIa engagement by rheumatoid arthritis-specific autoantibodies to citrullinated proteins complexed with fibrinogen","volume":"58","author":"Clavel","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2016.02.006_bb0030","doi-asserted-by":"crossref","first-page":"19396","DOI":"10.1073\/pnas.1014515107","article-title":"FcgammaRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo","volume":"107","author":"Nimmerjahn","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2016.02.006_bb0035","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nrd2909","article-title":"Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond","volume":"11","author":"Hogarth","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.autrev.2016.02.006_bb0040","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1136\/ard.2006.068981","article-title":"Treatment of lupus-prone NZB\/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32)","volume":"67","author":"Werwitzke","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2016.02.006_bb0045","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.clim.2008.02.002","article-title":"Amelioration of collagen-induced arthritis by human recombinant soluble FcgammaRIIb","volume":"127","author":"Magnusson","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2016.02.006_bb0050","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/jid.2014.451","article-title":"Recombinant soluble CD32 suppresses disease progression in experimental epidermolysis bullosa acquisita","volume":"135","author":"Iwata","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2016.02.006_bb0055","series-title":"ASH Annual Meeting and Exposition","article-title":"Interim Results From a Phase Ib\/IIa Clinical Trial with the Soluble Fc-Gamma IIb Receptor SM101 for the Treatment of Primary Immune Thrombocytopenia","author":"Konstaninova","year":"2012"},{"key":"10.1016\/j.autrev.2016.02.006_bb0060","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/nri3401","article-title":"Intravenous immunoglobulin therapy: how does IgG modulate the immune system?","volume":"13","author":"Schwab","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2016.02.006_bb0065","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/0140-6736(93)92000-J","article-title":"Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura","volume":"342","author":"Debre","year":"1993","journal-title":"Lancet"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2016.02.006_bb0070","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1007\/s10875-010-9410-9","article-title":"Adoptive-transfer effects of intravenous immunoglobulin in autoimmunity","volume":"30","author":"Lazarus","year":"2010","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.autrev.2016.02.006_bb0075","doi-asserted-by":"crossref","DOI":"10.1053\/j.seminhematol.2016.04.007","article-title":"Mechanistic properties of IVIg in murine ITP: support for Fc\u03b3RIIB falls by the wayside","author":"Crow","year":"2016","journal-title":"Semin Hematol"},{"key":"10.1016\/j.autrev.2016.02.006_bb0080","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1111\/trf.13032","article-title":"A monoclonal antibody with anti-D-like activity in murine immune thrombocytopenia requires Fc domain function for immune thrombocytopenia ameliorative effects","volume":"55","author":"Yu","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.autrev.2016.02.006_bb0085","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0037-1963(00)90104-5","article-title":"Fc receptor blockade and immune thrombocytopenic purpura","volume":"37","author":"Bussel","year":"2000","journal-title":"Semin Hematol"},{"key":"10.1016\/j.autrev.2016.02.006_bb0090","doi-asserted-by":"crossref","first-page":"R192","DOI":"10.1186\/ar4024","article-title":"Fully recombinant IgG2a Fc multimers (stradomers) effectively treat collagen-induced arthritis and prevent idiopathic thrombocytopenic purpura in mice","volume":"14","author":"Jain","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2016.02.006_bb0095","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/jns5.12022","article-title":"Beneficial effect of a multimerized immunoglobulin Fc in an animal model of inflammatory neuropathy (experimental autoimmune neuritis)","volume":"18","author":"Niknami","year":"2013","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.autrev.2016.02.006_bb0100","article-title":"Recombinant IgG2a Fc (M045) multimers effectively suppress experimental autoimmune myasthenia gravis","author":"Thiruppathi","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2016.02.006_bb0105","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2302\/kjm.60.37","article-title":"Therapeutic monoclonal antibodies","volume":"60","author":"Yamada","year":"2011","journal-title":"Keio J Med"},{"key":"10.1016\/j.autrev.2016.02.006_bb0110","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1073\/pnas.79.10.3275","article-title":"Human neutrophil Fc gamma receptor distribution and structure","volume":"79","author":"Fleit","year":"1982","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2016.02.006_bb0115","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1056\/NEJM198605083141907","article-title":"Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody","volume":"314","author":"Clarkson","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2016.02.006_bb0120","first-page":"2677","article-title":"Fc receptors in immune thrombocytopenias: a target for immunomodulation?","volume":"118","author":"Psaila","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2016.02.006_bb0125","series-title":"(Summary of 2 Pilot Studies), ASH Annual Meeting and Exposition","article-title":"3G8 and GMA161, Anti-Fc\u03b3RIII Inhibitory Monoclonal Antibodies in the Treatment of Chronic Refractory ITP","author":"Nakar","year":"2009"},{"key":"10.1016\/j.autrev.2016.02.006_bb0130","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/toxsci\/kfr278","article-title":"Nonclinical evaluation of GMA161\u2014an antihuman CD16 (FcgammaRIII) monoclonal antibody for treatment of autoimmune disorders in CD16 transgenic mice","volume":"125","author":"Flaherty","year":"2012","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.autrev.2016.02.006_bb0135","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jaci.2013.09.008","article-title":"Rapid desensitization of mice with anti-FcgammaRIIb\/FcgammaRIII mAb safely prevents IgG-mediated anaphylaxis","volume":"132","author":"Khodoun","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.autrev.2016.02.006_bb0140","series-title":"Decreased expression of CD200R3 on mouse basophils as a novel marker for IgG1-mediated anaphylaxis. Immun Inflamm Dis","author":"Iwamoto","year":"2015"},{"key":"10.1016\/j.autrev.2016.02.006_bb0145","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1067\/mai.2002.123302","article-title":"Pathways of anaphylaxis in the mouse","volume":"109","author":"Strait","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.autrev.2016.02.006_bb0150","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrd1033","article-title":"Effect of pegylation on pharmaceuticals","volume":"2","author":"Harris","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.autrev.2016.02.006_bb0155","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/978-1-61779-974-7_31","article-title":"Fc engineering: serum half-life modulation through FcRn binding","volume":"907","author":"Olafsen","year":"2012","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.autrev.2016.02.006_bb0160","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2016.02.006_bb0165","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1177\/1060028014545807","article-title":"Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes","volume":"48","author":"Trujillo","year":"2014","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.autrev.2016.02.006_bb0170","first-page":"269","article-title":"Metabolism and distribution of I-labelled albumin in the pig","volume":"27","author":"Dich","year":"1963","journal-title":"Can J Comp Med Vet Sci"},{"key":"10.1016\/j.autrev.2016.02.006_bb0175","first-page":"287","article-title":"Half-lives of homologous serum albumins in several species","volume":"83","author":"Dixon","year":"1953"},{"key":"10.1016\/j.autrev.2016.02.006_bb0180","first-page":"1608","article-title":"The catabolism of alpha1-fetoprotein and albumin in rats bearing Morris hepatoma 7777","volume":"34","author":"Sell","year":"1974","journal-title":"Cancer Res"},{"key":"10.1016\/j.autrev.2016.02.006_bb0185","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1113\/jphysiol.1961.sp006758","article-title":"Passage of plasma albumin into the intestine of the sheep","volume":"158","author":"Campbell","year":"1961","journal-title":"J Physiol"},{"key":"10.1016\/j.autrev.2016.02.006_bb0190","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1172\/JCI104594","article-title":"Studies of I-131-albumin catabolism and distribution in normal young male adults","volume":"41","author":"Beeken","year":"1962","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2016.02.006_bb0195","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1182\/blood-2015-08-664656","article-title":"Monovalent Fc receptor blockade by an anti-fcgamma receptor\/albumin fusion protein ameliorates murine ITP with abrogated toxicity","volume":"127","author":"Yu","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2016.02.006_bb0200","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2015-11-678680","article-title":"FcgammaRIII in ITP: it ain't over 'til it's over","volume":"127","author":"McCrae","year":"2016","journal-title":"Blood"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997216300325?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997216300325?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T11:03:32Z","timestamp":1752577412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997216300325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S1568997216300325"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2016.02.006","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting Fc\u03b3Rs to treat antibody-dependent autoimmunity","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2016.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2016 Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}